This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mankoff, D. A. Articles by Krohn, K. A. Search for Related Content PubMed PubMed Citation Articles by Mankoff, D. A. Articles by Krohn, K. A. Related Collections Cellular Pathobiology Cellular Pathobiology: Metabolism and Physiology Clinical Research Clinical Research: Imaging, Diagnosis, and Prognosis

Tumor-Specific Positron Emission Tomography Imaging in Patients: [¹⁸F] Fluorodeoxyglucose and Beyond

Authors' Affiliation: University of Washington and Seattle Cancer Care Alliance, Seattle, Washington

Requests for reprints: David A. Mankoff, Box 356113, Room NN203, University of Washington Medical Center, 1959 NE Pacific Street, Seattle, WA 98195. Phone: 206-288-2173; E-mail: dam{at}u.washington.edu.

Abstract

Biochemical and molecular imaging of cancer using positron emission tomography (PET) plays an increasing role in the care of cancer patients. Most clinical work to date uses the glucose analogue [¹⁸F]fluorodeoxyglucose (FDG) to detect accelerated and aberrant glycolysis present in most tumors. Although clinical FDG PET has been used largely to detect and localize cancer, more detailed studies have yielded biological insights and showed the utility of FDG as a prognostic marker and as a tool for therapeutic response evaluation. As cancer therapy becomes more targeted and individualized, it is likely that PET radiopharmaceuticals other than FDG, aimed at more specific aspects of cancer biology, will also play a role in guiding cancer therapy. Clinical trials designed to test and validate new PET agents will need to incorporate rigorous quantitative image analysis and adapt to the evolving use of imaging as a biomarker and will need to incorporate cancer outcomes, such as survival into study design.

This article has been cited by other articles:

				J. E Burdette In vivo imaging of molecular targets and their function in endocrinology J. Mol. Endocrinol., June 1, 2008; 40(6): 253 - 261. [Abstract] [Full Text] [PDF]

				D. A. Mankoff, J. M. Link, H. M. Linden, L. Sundararajan, and K. A. Krohn Tumor Receptor Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 149S - 163S. [Abstract] [Full Text] [PDF]

				G. C. Prendergast Non-Invasive Imaging: Enhancing Preclinical Research and Evidence-Based Medicine Cancer Reviews Online Content, July 1, 2007; 2007(4): 7 - 7. [Full Text] [PDF]

				R. G. Blasberg Imaging Update: New Windows, New Views Clin. Cancer Res., June 15, 2007; 13(12): 3444 - 3448. [Full Text] [PDF]